Sorfequiline-based treatment for new drug-sensitive TB
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests a new medicine called sorfequiline, given in a combination regimen, to treat adults with drug-sensitive TB. It aims to see if sorfequiline can work as well as or better than standard treatment and shorten the time to cure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of TB that is sensitive to the standard antibiotics (rifampin and isoniazid), or you were cured of TB before and haven't had treatment for at least 3 years.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study.
- You weigh at least 35 kilograms (about 77 pounds).
- You do not have TB that has spread outside your lungs (extrapulmonary TB).
- You do not have a serious heart condition or take medicines that affect your heart's rhythm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This trial tests whether a higher dose of the antibiotic rifampicin can shorten tuberculosis treatment from 6 months to 4 months. If you have drug-sensitive TB, this could mean fewer months of medication and fewer side effects.
This study tests a new tuberculosis drug called TBD09 combined with other TB medicines in people with newly diagnosed, drug-sensitive TB. The goal is to see if this combination works well and is safe.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.